Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 2/20 | 0.56 |
| ▸ | TP53 | P04637 | 2/20 | 0.56 |
| ▸ | CASP3 | P42574 | 2/20 | 0.53 |
| ▸ | MDM2 | Q00987 | 3/20 | 0.50 |
| ▸ | TLR2 | O60603 | 2/20 | 0.50 |
| ▸ | TNF | P01375 | 1/20 | 0.50 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL598209 | 1.00 | MDM4 (0.56) | MDM4TP53CASP3MDM2TLR2 | |
| SCHEMBL119565 | 1.00 | MDM4 (0.56) | MDM4TP53CASP3MDM2TLR2 | |
| SCHEMBL30802551 | 1.00 | MDM4 (0.56) | MDM4TP53CASP3MDM2TLR2 | |
| SCHEMBL29355082 | 1.00 | MDM4 (0.56) | MDM4TP53CASP3MDM2TLR2 | |
| SCHEMBL119575 | 1.00 | MDM4 (0.56) | MDM4TP53CASP3MDM2TLR2 | |
| SCHEMBL29624621 | 1.00 | MDM4 (0.56) | MDM4TP53CASP3MDM2TLR2 | |
| Fluoride SCHEMBL7155195 | 0.99 | MDM4 (0.55) | MDM4TP53CASP3MDM2TLR2 | |
| SCHEMBL30562127 | 0.96 | MDM4 (0.53) | MDM4TP53CASP3MDM2TLR2 | |
| SCHEMBL29400671 | 0.92 | MDM4 (0.52) | MDM4TP53CASP3MDM2TLR2 | |
| SCHEMBL9072218 | 0.91 | MDM4 (0.50) | MDM4TP53CASP3MDM2TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 171 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119529031-A | Cyclic peptide derivative and preparation method and application thereof | 润辉生物技术（威海）有限公司 | 2025-02-28 | — | — | CN | claimed |
| CN-117343128-A | Synthesis method of buserelin | 成都君诚康正生物科技有限公司 | 2024-01-05 | — | — | CN | claimed |
| CN-111233980-B | Fragment method synthesis method of goserelin | 南京礼威生物医药有限公司 | 2023-08-01 | — | — | CN | claimed |
| WO-2022266927-A1 | LIRAGLUTIDE VARIANT, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 深圳翰宇药业股份有限公司 | 2022-12-29 | — | — | WO | claimed |
| CN-113999289-A | Preparation method of goserelin | 杭州信海医药科技有限公司 | 2022-02-01 | — | — | CN | claimed |
| EP-4211146-B1 | SYNTHETIC CYCLIC PEPTIDE MIMETICS | UNIV BAR ILAN (IL) | 2026-05-20 | — | — | EP | disclosed |
| US-20260124313-A1 | SITE-SPECIFIC COVALENT LIGATION OF HUMAN SERUM ALBUMIN | UNIV CALIFORNIA (US) | 2026-05-07 | — | — | US | disclosed |
| US-12616761-B2 | CXCR4-targeting compounds | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2026-05-05 | — | — | US | disclosed |
| US-12616760-B2 | Synthetic cyclic peptide mimetics | BAR ILAN UNIVERSITY (IL) | 2026-05-05 | — | — | US | disclosed |
| EP-4725957-A1 | GROUP OF CYCLIC ALKALINE LIPOPEPTIDE COMPOUNDS, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences (CN) | 2026-04-15 | — | — | EP | disclosed |
| EP-4720097-A1 | PEPTIDES WITH LIPOLYTIC, ANTI-LIPOGENIC, ANTIFIBROTIC AND ANTI-INFLAMMATORY ACTIVITY | Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca (ES) | 2026-04-08 | — | — | EP | disclosed |
| EP-4696686-A1 | FAPI THERANOSTIC COMPOUNDS ASSEMBLED WITH TETRAZINE LIGATION | Tetrakit Technologies ApS (DK) | 2026-02-18 | — | — | EP | disclosed |
| WO-2022061924-A1 | GLP-1R/GCGR DUAL-TARGET AGONIST PEPTIDE DERIVATIVES FOR TREATMENT OF VIRAL HEPATITIS-RELATED HEPATIC FIBROSIS | 深圳市图微安创科技开发有限公司 | 2022-03-31 | — | — | WO | disclosed |
| WO-2022054062-A1 | SYNTHETIC CYCLIC PEPTIDE MIMETICS | BAR ILAN UNIVERSITY (IL) | 2022-03-17 | — | — | WO | disclosed |
| EP-3966234-A1 | VASCULAR CHOLESTEROL INHIBITORS AND USE THEREOF | Consejo Superior De Investigaciones Científicas (ES) | 2022-03-16 | — | — | EP | disclosed |
| WO-2022050529-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | ㈜베르티스 | 2022-03-10 | — | — | WO | disclosed |
| EP-3953333-A1 | NOVEL CYCLIC TREX1 INHIBITORS | Venenum Biodesign, LLC (US) | 2022-02-16 | — | — | EP | disclosed |
| CN-113999289-A | Preparation method of goserelin | 杭州信海医药科技有限公司 | 2022-02-01 | — | — | CN | disclosed |
| CN-113999289-A | Preparation method of goserelin | 杭州信海医药科技有限公司 | 2022-02-01 | — | — | CN | disclosed |
| WO-2022018264-A1 | SILICON-CONTAINING LIGAND COMPOUNDS | Technische Universität München (DE) | 2022-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12616760-B2 | Synthetic cyclic peptide mimetics | TPX2, IAPP, HAX1 | MDM4 1931/4885TP53 805/4885CASP3 1335/4885 |
| US-20260124313-A1 | SITE-SPECIFIC COVALENT LIGATION OF HUMAN SERUM ALBUMIN | GLP1R, ALB, GIPR | MDM4 4874/4885TP53 2182/4885CASP3 1790/4885 |
| US-12616761-B2 | CXCR4-targeting compounds | CXCR4, CXCR2, CXCR3 | MDM4 3817/4885TP53 1733/4885CASP3 3114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.